Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone app aims to tame diabetes with personalized lifestyle tips

NCT ID NCT07160998

Disease control Sponsor: Li Huating Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested an AI-based system called X-Life that gives personalized lifestyle advice to adults with type 2 diabetes. The system uses glucose levels and wearable data to guide diet and activity. 124 participants were split into two groups: one using X-Life and the other receiving standard care. The main goal was to see if the AI system helped people spend more time in a healthy glucose range.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Digital Lifestyle Therapeutic (AI-based lifestyle guidance system X-Life)
What this could lead to
If successful, this could point toward a more personalized, tech-driven way to manage type 2 diabetes, potentially improving glucose control without extra medication.
What could go wrong
This is a completed early-stage study with only 124 participants. The AI system may not work for everyone, and results may not apply to people on insulin or with complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

124 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years * Diagnosed type 2 diabetes * Stable medication regimen ≥ 3 months * HbA1c 7-10% * Smartphone access and ability to operate app * Willing to wear CGM and activity tracker * Able to provide informed consent Exclusion Criteria: * Insulin therapy * Severe chronic/acute diabetic complications * Early-onset diabetes (\<40 years at diagnosis) * Severe cardiovascular disease, uncontrolled hypertension, active liver disease, malignancy * Severe psychiatric or cognitive disorders * Allergy to CGM materials * Planned surgery or long-term travel during study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • Shanghai Sixth People's Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.